<DOC>
	<DOCNO>NCT02269059</DOCNO>
	<brief_summary>This two-part dose-finding trial MK-7680 participant Hepatitis C Virus ( HCV ) infection genotype ( GT ) 1 ( Part I ) GT3 ( Part 2 ) . The primary hypothesis daily administration safe well tolerate dose MK-7680 produce decrease HCV viral load .</brief_summary>
	<brief_title>Safety Pharmacokinetics MK-7680 Participants With Hepatitis C ( MK-7680-003 )</brief_title>
	<detailed_description>Parts 1 2 consist 4 panel . In first panel , 200 mg dose MK-7680 administered . In follow 3 panel , high low dos MK-7680 administer . Each panel begin safety tolerability data precede panel evaluate .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Is good health except HCV infection Is male female nonchildbearing potential Clinical diagnosis HCV GT1 GT3 evidence mixedGT nontypeable infection Has history clinically significant stably control endocrine , gastrointestinal , cardiovascular , hematological , hepatic ( except HCV infection ) , immunological , renal , respiratory , genitourinary , major neurological abnormality disease Has history cancer Has history significant multiple and/or severe allergy Is positive hepatitis B human immunodeficiency virus Has major surgery , donate lose 1 unit ( 500 mL ) blood within 4 week prior screen Consumes 2 alcoholic beverage per day currently regular user illicit drug ( ) history alcohol/drug abuse within 12 month prior screen Has chronic hepatitis cause HCV ( e.g. , nonalcoholic steatohepatitis [ NASH ] ) Has clinical laboratory evidence advance decompensated liver disease , evidence bridge high grade fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>